Exacerbation of ulcerative colitis during alpha-interferon therapy for chronic hepatitis C. 1993

A Mitoro, and M Yoshikawa, and K Yamamoto, and M Mimura, and Y Yoshikawa, and A Shiroi, and T Mochi, and T Sakamoto, and J Yamao, and E Kikuchi
Department of Gastroenterology, Hattori Memorial Hospital, Nara, Japan.

We report a 34-year-old man with chronic hepatitis C who showed exacerbation of ulcerative colitis during alpha-interferon (IFN alpha) therapy. Discontinuance of the IFN alpha therapy improved his symptoms, suggesting that IFN alpha administration might worsen ulcerative colitis. The administration of sulfasalazine allowed the patient to receive IFN alpha again without flare-up of ulcerative colitis. This case suggests the possible efficacy of sulfasalazine therapy in patients with ulcerative colitis complicated by some other diseases requiring IFN alpha administration.

UI MeSH Term Description Entries
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D008297 Male Males
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D003093 Colitis, Ulcerative Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN. Colitis Gravis,Idiopathic Proctocolitis,Inflammatory Bowel Disease, Ulcerative Colitis Type,Ulcerative Colitis
D006526 Hepatitis C INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown. Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted,Parenterally-Transmitted Non-A, Non-B Hepatitis,PT-NANBH,Parenterally Transmitted Non A, Non B Hepatitis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001327 Autoimmune Diseases Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides. Autoimmune Disease,Disease, Autoimmune,Diseases, Autoimmune
D012460 Sulfasalazine A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907) Salicylazosulfapyridine,Asulfidine,Azulfadine,Azulfidine,Azulfidine EN,Colo-Pleon,Pleon,Pyralin EN,Salazopyrin,Salazosulfapyridine,Sulfasalazin medac,Sulfasalazin-Heyl,Sulfasalazine FNA,Sulphasalazine,Ucine,Ulcol,ratio-Sulfasalazine,Colo Pleon,Sulfasalazin Heyl,ratio Sulfasalazine

Related Publications

A Mitoro, and M Yoshikawa, and K Yamamoto, and M Mimura, and Y Yoshikawa, and A Shiroi, and T Mochi, and T Sakamoto, and J Yamao, and E Kikuchi
August 1994, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
A Mitoro, and M Yoshikawa, and K Yamamoto, and M Mimura, and Y Yoshikawa, and A Shiroi, and T Mochi, and T Sakamoto, and J Yamao, and E Kikuchi
September 2006, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology,
A Mitoro, and M Yoshikawa, and K Yamamoto, and M Mimura, and Y Yoshikawa, and A Shiroi, and T Mochi, and T Sakamoto, and J Yamao, and E Kikuchi
October 2006, Canadian journal of gastroenterology = Journal canadien de gastroenterologie,
A Mitoro, and M Yoshikawa, and K Yamamoto, and M Mimura, and Y Yoshikawa, and A Shiroi, and T Mochi, and T Sakamoto, and J Yamao, and E Kikuchi
April 2011, Inflammatory bowel diseases,
A Mitoro, and M Yoshikawa, and K Yamamoto, and M Mimura, and Y Yoshikawa, and A Shiroi, and T Mochi, and T Sakamoto, and J Yamao, and E Kikuchi
June 1995, Digestive diseases and sciences,
A Mitoro, and M Yoshikawa, and K Yamamoto, and M Mimura, and Y Yoshikawa, and A Shiroi, and T Mochi, and T Sakamoto, and J Yamao, and E Kikuchi
August 1996, Journal of gastroenterology,
A Mitoro, and M Yoshikawa, and K Yamamoto, and M Mimura, and Y Yoshikawa, and A Shiroi, and T Mochi, and T Sakamoto, and J Yamao, and E Kikuchi
July 1995, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology,
A Mitoro, and M Yoshikawa, and K Yamamoto, and M Mimura, and Y Yoshikawa, and A Shiroi, and T Mochi, and T Sakamoto, and J Yamao, and E Kikuchi
June 2001, Journal of hepatology,
A Mitoro, and M Yoshikawa, and K Yamamoto, and M Mimura, and Y Yoshikawa, and A Shiroi, and T Mochi, and T Sakamoto, and J Yamao, and E Kikuchi
January 1992, Digestion,
A Mitoro, and M Yoshikawa, and K Yamamoto, and M Mimura, and Y Yoshikawa, and A Shiroi, and T Mochi, and T Sakamoto, and J Yamao, and E Kikuchi
June 2000, Clinical and experimental dermatology,
Copied contents to your clipboard!